Connection

Stephen Tomlinson to Animals

This is a "connection" page, showing publications Stephen Tomlinson has written about Animals.
Connection Strength

2.323
  1. A Role of Complement in the Pathogenic Sequelae of Mouse Neonatal Germinal Matrix Hemorrhage. Int J Mol Sci. 2022 Mar 09; 23(6).
    View in: PubMed
    Score: 0.059
  2. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
    View in: PubMed
    Score: 0.057
  3. Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study. Acta Neuropathol Commun. 2021 07 19; 9(1):126.
    View in: PubMed
    Score: 0.056
  4. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
    View in: PubMed
    Score: 0.056
  5. Complement mediates neuroinflammation and cognitive decline at extended chronic time points after traumatic brain injury. Acta Neuropathol Commun. 2021 04 20; 9(1):72.
    View in: PubMed
    Score: 0.055
  6. Complement Drives Synaptic Degeneration and Progressive Cognitive Decline in the Chronic Phase after Traumatic Brain Injury. J Neurosci. 2021 02 24; 41(8):1830-1843.
    View in: PubMed
    Score: 0.054
  7. Complement-Mediated Microglial Phagocytosis and Pathological Changes in the Development and Degeneration of the Visual System. Front Immunol. 2020; 11:566892.
    View in: PubMed
    Score: 0.053
  8. Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here? Front Immunol. 2020; 11:2021.
    View in: PubMed
    Score: 0.053
  9. Complement-Dependent Synaptic Uptake and Cognitive Decline after Stroke and Reperfusion Therapy. J Neurosci. 2020 05 13; 40(20):4042-4058.
    View in: PubMed
    Score: 0.051
  10. Acute Complement Inhibition Potentiates Neurorehabilitation and Enhances tPA-Mediated Neuroprotection. J Neurosci. 2018 07 18; 38(29):6527-6545.
    View in: PubMed
    Score: 0.045
  11. Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice. Sci Transl Med. 2018 05 16; 10(441).
    View in: PubMed
    Score: 0.045
  12. Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury. J Neurosci. 2018 03 07; 38(10):2519-2532.
    View in: PubMed
    Score: 0.044
  13. Natural immunoglobulin M initiates an inflammatory response important for both hepatic ischemia reperfusion injury and regeneration in mice. Hepatology. 2018 02; 67(2):721-735.
    View in: PubMed
    Score: 0.044
  14. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement. J Neuroinflammation. 2017 06 19; 14(1):120.
    View in: PubMed
    Score: 0.042
  15. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
    View in: PubMed
    Score: 0.042
  16. Injury site-specific targeting of complement inhibitors for treating stroke. Immunol Rev. 2016 11; 274(1):270-280.
    View in: PubMed
    Score: 0.040
  17. Thromboembolic Model of Cerebral Ischemia and Reperfusion in Mice. Methods Mol Biol. 2016; 1462:357-72.
    View in: PubMed
    Score: 0.038
  18. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation. 2015 Dec 30; 12:247.
    View in: PubMed
    Score: 0.038
  19. Complementing regeneration. Oncotarget. 2015 Sep 08; 6(26):21769-70.
    View in: PubMed
    Score: 0.037
  20. Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis. Clin Exp Immunol. 2015 Mar; 179(3):500-8.
    View in: PubMed
    Score: 0.036
  21. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
    View in: PubMed
    Score: 0.036
  22. Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. J Exp Med. 2014 Aug 25; 211(9):1793-805.
    View in: PubMed
    Score: 0.035
  23. A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis. Clin Exp Immunol. 2014 Aug; 177(2):500-8.
    View in: PubMed
    Score: 0.035
  24. Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Rep. 2014 Aug 07; 8(3):818-30.
    View in: PubMed
    Score: 0.035
  25. Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation. 2013 Mar 26; 127(12):1290-9.
    View in: PubMed
    Score: 0.031
  26. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol. 2013; 735:137-54.
    View in: PubMed
    Score: 0.031
  27. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol. 2012 Nov 01; 189(9):4640-7.
    View in: PubMed
    Score: 0.030
  28. Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol. 2012 Jun 15; 188(12):6309-18.
    View in: PubMed
    Score: 0.030
  29. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
    View in: PubMed
    Score: 0.029
  30. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol. 2012 Feb 01; 188(3):1460-8.
    View in: PubMed
    Score: 0.029
  31. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol. 2011 Oct; 49(1-2):317-23.
    View in: PubMed
    Score: 0.028
  32. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 2011 Apr; 63(4):1076-85.
    View in: PubMed
    Score: 0.027
  33. Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol. 2010 Dec 01; 185(11):7007-13.
    View in: PubMed
    Score: 0.027
  34. The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am J Pathol. 2010 Dec; 177(6):3061-70.
    View in: PubMed
    Score: 0.027
  35. Ketamine-xylazine-acepromazine compared with isoflurane for anesthesia during liver transplantation in rodents. J Am Assoc Lab Anim Sci. 2010 Jan; 49(1):45-51.
    View in: PubMed
    Score: 0.025
  36. Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res. 2009 Nov 20; 105(11):1094-101.
    View in: PubMed
    Score: 0.025
  37. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol. 2009 Oct 01; 183(7):4764-72.
    View in: PubMed
    Score: 0.025
  38. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest. 2009 Aug; 119(8):2304-16.
    View in: PubMed
    Score: 0.024
  39. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009 Jul; 50(7):3056-64.
    View in: PubMed
    Score: 0.024
  40. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
    View in: PubMed
    Score: 0.023
  41. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res. 2008 Aug 15; 68(16):6734-42.
    View in: PubMed
    Score: 0.023
  42. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol. 2008 Jan 15; 180(2):1231-8.
    View in: PubMed
    Score: 0.022
  43. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
    View in: PubMed
    Score: 0.022
  44. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res. 2007 Oct 01; 67(19):9535-41.
    View in: PubMed
    Score: 0.022
  45. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol. 2006 Nov 15; 177(10):7266-74.
    View in: PubMed
    Score: 0.020
  46. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol. 2006 Sep; 169(3):1039-47.
    View in: PubMed
    Score: 0.020
  47. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. 2005 Nov 15; 65(22):10562-8.
    View in: PubMed
    Score: 0.019
  48. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
    View in: PubMed
    Score: 0.019
  49. Insights into the human CD59 complement binding interface toward engineering new therapeutics. J Biol Chem. 2005 Oct 07; 280(40):34073-9.
    View in: PubMed
    Score: 0.019
  50. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol. 2005 May 01; 174(9):5750-7.
    View in: PubMed
    Score: 0.018
  51. Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma. Int J Cancer. 2004 Jul 20; 110(6):875-81.
    View in: PubMed
    Score: 0.017
  52. The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology. 2004 Mar; 111(3):291-7.
    View in: PubMed
    Score: 0.017
  53. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003 Jun; 111(12):1875-85.
    View in: PubMed
    Score: 0.016
  54. Crosstalk between pro-survival sphingolipid metabolism and complement signaling induces inflammasome-mediated tumor metastasis. Cell Rep. 2022 12 06; 41(10):111742.
    View in: PubMed
    Score: 0.015
  55. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res. 2002 Feb 15; 62(4):1110-5.
    View in: PubMed
    Score: 0.015
  56. Complement Inhibition Alleviates Cholestatic Liver Injury Through Mediating Macrophage Infiltration and Function in Mice. Front Immunol. 2021; 12:785287.
    View in: PubMed
    Score: 0.014
  57. Modulation of the Complement System by Neoplastic Disease of the Central Nervous System. Front Immunol. 2021; 12:689435.
    View in: PubMed
    Score: 0.014
  58. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
    View in: PubMed
    Score: 0.014
  59. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem. 2001 Jul 20; 276(29):27290-5.
    View in: PubMed
    Score: 0.014
  60. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.
    View in: PubMed
    Score: 0.014
  61. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.
    View in: PubMed
    Score: 0.014
  62. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.
    View in: PubMed
    Score: 0.013
  63. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. Clin Cancer Res. 2020 07 01; 26(13):3481-3490.
    View in: PubMed
    Score: 0.013
  64. Complement C3 activation regulates the production of tRNA-derived fragments Gly-tRFs and promotes alcohol-induced liver injury and steatosis. Cell Res. 2019 07; 29(7):548-561.
    View in: PubMed
    Score: 0.012
  65. Inhibition of the alternative complement pathway accelerates repair processes in the murine model of choroidal neovascularization. Mol Immunol. 2019 04; 108:8-12.
    View in: PubMed
    Score: 0.012
  66. Acid sphingomyelinase deficiency protects mitochondria and improves function recovery after brain injury. J Lipid Res. 2019 03; 60(3):609-623.
    View in: PubMed
    Score: 0.012
  67. CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma. Cell Death Dis. 2019 01 18; 10(2):52.
    View in: PubMed
    Score: 0.012
  68. Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight. 2018 12 20; 3(24).
    View in: PubMed
    Score: 0.012
  69. Sialic acid is a critical fetal defense against maternal complement attack. J Clin Invest. 2019 01 02; 129(1):422-436.
    View in: PubMed
    Score: 0.012
  70. Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved ?2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury. J Neurotrauma. 2019 03 19; 36(6):962-972.
    View in: PubMed
    Score: 0.012
  71. Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma. Mol Ther. 2018 10 03; 26(10):2379-2396.
    View in: PubMed
    Score: 0.011
  72. C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunol. 2018 09; 11(5):1375-1385.
    View in: PubMed
    Score: 0.011
  73. Preclinical and Clinical Evidence on Ipsilateral Corticospinal Projections: Implication for Motor Recovery. Transl Stroke Res. 2017 12; 8(6):529-540.
    View in: PubMed
    Score: 0.011
  74. New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement. J Ocul Pharmacol Ther. 2017 06; 33(5):400-411.
    View in: PubMed
    Score: 0.010
  75. Surface Expression of TGF? Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. Cancer Res. 2016 12 15; 76(24):7106-7117.
    View in: PubMed
    Score: 0.010
  76. Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell-Like Behaviors in Hepatocellular Carcinoma. Cancer Res. 2016 11 15; 76(22):6520-6532.
    View in: PubMed
    Score: 0.010
  77. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
    View in: PubMed
    Score: 0.010
  78. A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Invest Ophthalmol Vis Sci. 2016 Apr; 57(4):1728-37.
    View in: PubMed
    Score: 0.010
  79. Early Application of Auxiliary Partial Orthotopic Liver Transplantation in Murine Model of Wilson Disease. Transplantation. 2015 Nov; 99(11):2317-24.
    View in: PubMed
    Score: 0.009
  80. Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency. J Immunol. 2015 Aug 01; 195(3):1129-38.
    View in: PubMed
    Score: 0.009
  81. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease. Mol Immunol. 2015 Feb; 63(2):479-88.
    View in: PubMed
    Score: 0.009
  82. Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. J Cell Biochem. 2015 Jan; 116(1):102-14.
    View in: PubMed
    Score: 0.009
  83. IL-1a and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells. PLoS Pathog. 2014 Mar; 10(3):e1004035.
    View in: PubMed
    Score: 0.008
  84. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. Atherosclerosis. 2014 May; 234(1):237-43.
    View in: PubMed
    Score: 0.008
  85. The complement regulatory protein CD59: insights into attenuation of choroidal neovascularization. Adv Exp Med Biol. 2014; 801:435-40.
    View in: PubMed
    Score: 0.008
  86. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. 2013 Aug; 49(2):221-30.
    View in: PubMed
    Score: 0.008
  87. Upregulation of the d opioid receptor in liver cancer promotes liver cancer progression both in vitro and in vivo. Int J Oncol. 2013 Oct; 43(4):1281-90.
    View in: PubMed
    Score: 0.008
  88. Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6877-82.
    View in: PubMed
    Score: 0.008
  89. Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6061-6.
    View in: PubMed
    Score: 0.008
  90. A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
    View in: PubMed
    Score: 0.008
  91. Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. Neurosci Lett. 2012 Nov 30; 531(1):35-9.
    View in: PubMed
    Score: 0.008
  92. The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria. J Biol Chem. 2012 Jul 13; 287(29):24734-8.
    View in: PubMed
    Score: 0.007
  93. Oval cell response is attenuated by depletion of liver resident macrophages in the 2-AAF/partial hepatectomy rat. PLoS One. 2012; 7(4):e35180.
    View in: PubMed
    Score: 0.007
  94. The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol. 2012 Jan 15; 188(2):661-7.
    View in: PubMed
    Score: 0.007
  95. Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure. PLoS One. 2011; 6(11):e26838.
    View in: PubMed
    Score: 0.007
  96. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
    View in: PubMed
    Score: 0.007
  97. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int. 2011 Jul; 80(2):165-73.
    View in: PubMed
    Score: 0.007
  98. Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. J Biol Chem. 2011 Jun 10; 286(23):20952-62.
    View in: PubMed
    Score: 0.007
  99. Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol. 2011 Oct; 45(4):834-42.
    View in: PubMed
    Score: 0.007
  100. Macrophage-produced IL-12p70 mediates hemorrhage-induced damage in a complement-dependent manner. Shock. 2011 Feb; 35(2):134-40.
    View in: PubMed
    Score: 0.007
  101. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol. 2011 Mar; 48(6-7):e1-8.
    View in: PubMed
    Score: 0.007
  102. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011 Feb; 79(3):331-9.
    View in: PubMed
    Score: 0.007
  103. Complement regulates TLR4-mediated inflammatory responses during intestinal ischemia reperfusion. Mol Immunol. 2010 Nov-Dec; 48(1-3):356-64.
    View in: PubMed
    Score: 0.007
  104. A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J. 2010 Feb 09; 7:30.
    View in: PubMed
    Score: 0.006
  105. A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49.
    View in: PubMed
    Score: 0.006
  106. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol. 2009 Nov 01; 183(9):5928-37.
    View in: PubMed
    Score: 0.006
  107. App1: an antiphagocytic protein that binds to complement receptors 3 and 2. J Immunol. 2009 Jan 01; 182(1):84-91.
    View in: PubMed
    Score: 0.006
  108. Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol. 2008 Sep; 74(3):574-84.
    View in: PubMed
    Score: 0.006
  109. Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res. 2006 Jun 15; 66(12):6258-63.
    View in: PubMed
    Score: 0.005
  110. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
    View in: PubMed
    Score: 0.005
  111. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo. J Immunol. 2004 Jul 01; 173(1):205-13.
    View in: PubMed
    Score: 0.004
  112. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004 Mar; 25(3):158-64.
    View in: PubMed
    Score: 0.004
  113. A novel murine P-450 gene, Cyp4a14, is part of a cluster of Cyp4a and Cyp4b, but not of CYP4F, genes in mouse and humans. Biochem J. 1997 Aug 01; 325 ( Pt 3):741-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.